Skip to content
School of Pharmacy

expertise: Pharmaceutical Policy

Jing Li

Education

  • PhD, Health Policy (Economics Track), University of California at Berkeley, 2016
  • MS, Economics, University of California at Berkeley, 2015
  • MA, International Comparative Education, Stanford University, 2009
  • BA, Economics and English, Peking University, China, 2008

Courses Taught

  • HEOR 597: Graduate Seminar
  • HEOR 598: HEOR Methodologies Seminar

Research Interests

  • Decision-making in Aging
  • Physician Behavior
  • Policy Evaluation
  • Experimental and Quasi-experimental Methods

Biography

Dr. Jing Li is a health economist with research interests in the economic, social and behavioral factors affecting individual decision-making in health and healthcare, for both providers and patients, and the impact of policies that leverage these factors to improve patient outcomes and healthcare market efficiency. Methodologically, she is interested in innovatively applying advanced experimental and econometric methods to addressing understudied questions in health economics and policy. Dr. Li’s current projects study experimentally measured social preferences (altruism) of physicians and their relationship with patient outcomes, healthcare and financial decision-making for older adults with cognitive impairments including Alzheimer’s disease and related dementias, and conflicts of interest in physician drug prescribing.

Selected Publications

https://www.ncbi.nlm.nih.gov/myncbi/jing.li.13/bibliography/public/

Tom Hazlet

Education

  • DrPH in Health Policy & Administration, University of California, Berkeley
  • PharmD, University of California, San Francisco
  • Bachelor of Science in Biology, University of Redlands

Research Interests

  • Regulation of medical products

Courses Taught

  • Pharm 516-518 Biomedical Regulatory Affairs
  • Pharm 532 Medical Products Policy Analysis
  • Pharm 543 Pharmacy Law & Ethics
  • Phrmra 548 BRAMS Practicum

Biography

1968-72 — Industrial microbiologist for a biologics manufacturer
1973-77 — University of California San Francisco — PharmD
1977-78 — Yale-New Haven Hospital — residency
1978-84 — UCLA Hospital — parenteral nutrition
1984-96 — Sutter Solano Hospital (part time after 1986)
1986-91 — University of California Berkeley — DrPH
1998-96 — California Department of Health Services; seconded to US Food and Drug Administration
1996-present — University of Washington School of Pharmacy
2007-present — Director, Biomedical Regulatory Affairs MS (BRAMS)

Selected Publications

  • Karwaki TE & Hazlet TK. A qualitative analysis of student-written law and ethics cases: A snapshot of PY2 student experience. CPTL. 2017
  • Hazlet TK, Karwaki TE, Downing DF. Pathway to pharmacist medical provider status in Washington State. J Am Pharm Assoc (2003). 2017 Jan – Feb;57(1):116-119.
  • Chan LN, Soltani H, Hazlet TK. Probiotics for neonates: safety for prime time questioned without regulatory changes. J Pediatr. 2015 Feb;166(2):502
  • Austin SC, Hammer D, Hazlet T, et al. An educational technology student and faculty needs assessment. PHARMACOTHERAPY 2012; 32(10): E287-E287

Ryan Hansen

Education

  • PhD in Pharmaceutical Outcomes Research and Policy, UW
  • PharmD, UW
  • Bachelor of Arts in Chemistry and Philosophy, Carroll College

Research Interests

  • Cost-effectiveness modeling
  • Comparative effectiveness research
  • Medication safety

Courses Taught

  • PHRMCY 512: Fundamentals of US Health Care, Pharmacy Safety and Law
  • HEOR 505: Managed Care Pharmacy
  • HEOR 530: Economic Evaluation in Health and Medicine
  • HEOR 532: Advanced Methods in Economic Evaluation
  • HEOR 545: Pharmaceutical and Medical Policy Evaluation
  • HEOR 597: Graduate Seminar

Biography
Dr. Hansen is Professor of Pharmacy and Chair of the Department of Pharmacy. His primary research interests focus on the comparative safety of prescription medications, health technology assessment, and health care system efficiency. He received his Bachelor of Arts from Carroll College, and his Doctor of Pharmacy and Doctor of Philosophy from the University of Washington.

Selected Recent Publications

Elsisi, Z, Canestaro WJ, Steuten L, Hansen RN. Applying Early Health Technology Assessment (e-HTA) to Inform Investment in Novel Health Technologies in the US. International Journal of Technology Assessment in Health Care 2025. In Press.

Gold LS, Heagerty PJ, Hansen RN, Friedly JL, Johnston SK, Deyo RA, Curatolo M, Turner JA, Rundell SD, Wysham K, Jarvik JG, Suri P. Adverse respiratory events during treatment with gabapentin and opioids among older adults with spine-related conditions: a propensity-matched cohort study in the US Medicare population. Spine 2025. In Press.

Hernandez I, Gabriel N, Pathak Y, Hansen RN, Sullivan SD, Fendrick AM. Projected Out of Pocket Savings of the Medicare Part D Two Dollar Drug List Model. JAMA 2025. In Press.

Hernandez I, Gabriel N, Pathak Y, Hansen RN, Sullivan SD. Overpayment for Generic Drugs under Medicare Part D: Consequences on Patient Out-of-Pocket Costs. JAMA Health Forum 2025;6(2):e250012.

Gold LS, Heagerty PJ, Hansen RN, Friedly JL, Johnston SK, Deyo RA, Curatolo M, Turner JA, Rundell SD, Wysham K, Jarvik JG, Suri P. Mortality after concurrent treatment with gabapentin and opioids in older adults with spine diagnoses. PAIN 2024. In Press.

Cousin EM, Sullivan SD, Hansen RN, Gabriel N, Kirihennedige AS, Hernandez I. Drugs Anticipated to Be Selected for Medicare Price Negotiation in 2025 for Implementation in 2027. Journal of Managed Care & Specialty Pharmacy 2024;30(11): 1203-1210.

Tran J, Mishra A, Zimmerman M, Hansen RN. Bridging PrEP Access Gaps: Mapping Geospatial Accessibility Across the US and Leveraging Community Pharmacies for Expansion. Journal of the American Pharmacists Association 2024. In Press.

Hernandez I, Sullivan SD, Hansen RN, Fendrick AM. Cheaper Isn’t Always Better: Drug Shortages in the U.S. and A Value-Based Solution to Alleviate Them. Journal of Managed Care & Specialty Pharmacy 2024;30(7):719-26.

Tsui JI, Gojic AJ, Pierce KA, Tung EL, Connolly NC, Radick AC, Hunt RR, Sandvold R, Taber K, Kubiniec RH, Scott JD, Hansen RN, Stekler JD, Austin EJ, Williams EC, Glick SN. Pilot study of a community pharmacist led program to treat hepatitis C virus among people who inject drugs. Drug and Alcohol Dependence Reports 2024. In Press.

Green TC, Silcox J, Bolivar D, Gray M, Floyd AS, Irwin AN, Hansen RN, Hartung D, Bratberg J. Pharmacy staff-reported adaptations to naloxone provision and over the counter (OTC) syringe sales during the COVID-19 pandemic: experiences across multiple states and two pharmacy chains. Journal of the American Pharmacists Association 2024;64(1):71-78.

Hernandez I, Gabriel N, Kaltenboeck A, Boccuti C, Hansen RN, Sullivan SD. Reimbursement to Pharmacies for Generic Drugs by Medicare Part D Sponsors. JAMA 2023;330(24):2390-92.

Tabah A, Gold LS, Marcum ZA, Hansen RN. Antidepressants and the Risk of Fall-related Injury in Older Adults with Incident Depression in the United States: A Comparative Safety Analysis. Pharmacoepidemiology 2023. In Press.

Bacci, JL, Marcum ZA, Rodriguez P, Hansen RN, Bansal A, Pfund T, Kim JJ, Odegard P. Community pharmacist intervention to optimize statin adherence in diabetes care: The GuIDE-S study. Journal of the American Pharmacists Association 2023;63(3):946-51.

Jiao B, Fredricks DN, Srinivasan S, Hansen RN. Economic Evaluation of a Point-of-Care Test for Bacterial Vaginosis among Women with Vaginal Symptoms. Sexually Transmitted Diseases 2023;50(5):310-6.

Jiang S, Seslar SP, Sloan LA, Hansen RN. Healthcare Resource Utilization and Costs Associated with Atrial Fibrillation and Rural-urban Disparities. Journal of Managed Care and Specialty Pharmacy 2022;28(11):1321-30.

Nitkin D, Lin GA, Campbell JC, Hansen RN, Brouwer E, Chen Y, Herron-Smith S, Agboola F, Pearson SD. The Effectiveness and Value of Tirzepatide for Type 2 Diabetes Mellitus. Journal of Managed Care and Specialty Pharmacy 2022;28(6):680-4.

Ko GC, Hansen RN, Carlson JJ. Comparing Costs and Healthcare Resource Utilization Between nmHSPC and mHSPC Patients: A Retrospective Claims Analysis. Journal of Managed Care and Specialty Pharmacy 2022;28(3):287-95.

Agboola F, Atlas SJ, Brouwer E, Carlson JJ, Hansen RN, Herron-Smith S, Nhan E, Rind DM, Pearson SD. JAK Inhibitors and Monoclonal Antibodies for the Treatment of Atopic Dermatitis: Effectiveness and Value. Journal of Managed Care and Specialty Pharmacy 2022;28(1):108-14.

Bratburg J, Irwin A, Hartung D, Floyd A, Bogis J, Hansen RN, Green T. Study Protocol for the Respond to Prevent Study: A multi-state randomized controlled trial to improve provision of naloxone, buprenorphine and nonprescription syringes in community pharmacies. Substance Abuse 2022;41(3):901-5.

Hansen RN, Saour B, Serafini B, Hannaford B, Kim L, Kohno T, James R, Monsky W, Seslar S. Opportunities and Barriers to Rural Telerobotic Surgical Healthcare in 2021: Report and Research Agenda from a Stakeholder Workshop. Telemedicine and e-Health 2022;28(7):1050-7.

Tsui JI, Barry MP, Austin EJ, Sweek EW, Tung E, Hansen RN, Ninburg M, Scott JD, Glick SN, Williams EC. ‘Treat my whole person, not just my condition’: Qualitative explorations of Hepatitis C care delivery preferences among people who inject drugs. Addiction Science and Clinical Practice 2021;16 (1):52.

Pocobelli G, Akosile MA, Hansen RN, Eavey J, Wellman RD, Johnson RL, Carls G, Bron M, Dublin S. Obstructive Sleep Apnea and Risk of Motor Vehicle Accident. Sleep Medicine 2021;85:196-203.

Banta-Green CJ, Hansen RN, Ossiander EM, Wasserman CR, Merrill JO. Buprenorphine utilization among all Washington State residents based upon prescription monitoring program data- Characteristics associated with two measures of retention and patterns of care over time. Journal of Substance Abuse Treatment 2021;127:108446 epub.

Brouwer E, Yeung K, Barthold D, Hansen RN. Characterizing patient assistance program use and patient responsiveness to specialty drug price for multiple sclerosis in one mid-size integrated health system. Journal of Managed Care and Specialty Pharmacy 2021;27(6):732-42.

Guzauskas GF, Rind DM, Fazioli K, Chapman RH, Pearson SD, Hansen RN. Cost-Effectiveness of Oral Semaglutide Added to Current Antihyperglycemic Treatment for Type 2 Diabetes. Journal of Managed Care and Specialty Pharmacy 2021;27(4):455-68.

Landaas EJ, Baird GS, Hansen RN, Flum DR, Sullivan SD. Integrating Formal Technology Assessment into an Integrated Healthcare Delivery System: Smart Innovation. International Journal of Health Technology Assessment in Health Care 2020;36(1):58-63.

Tice JA, Guzauskas GF, Hansen RN, Herron-Smith S, Segel C, Walsh JME, Pearson SD. The Effectiveness and Value of Oral Immunotherapy and Viaskin Peanut for Peanut Allergy. Journal of Managed Care and Specialty Pharmacy 2020;26(5):620-3.

Gold LS, Nazareth TA, Yu T, Fry KR, Mahler N, Rava A, Waltrip RW, Hansen RN. Medication Utilization Patterns 90 Days Before Initiation of Treatment with Repository Corticotropin Injection in Patients with Infantile Spasms. Pediatric Health, Medicine and Therapeutics 2019;10:195-207.

Gold LS, Patrick DL, Hansen RN, Goss CH, Kessler L. Correspondence between Lung Function and Symptom Measures from the Cystic Fibrosis Respiratory Symptom Diary-Chronic Respiratory Infection Symptom Score (CFRSD-CRISS). Journal of Cystic Fibrosis 2019;18(6):886-93.

Bacci JL, Hansen RN, Ree C, Reynolds MJ, Stergachis A, Odegard PS. The effects of vaccination forecasts and value-based payment on adult immunizations by community pharmacists. Vaccine 2019;37(1):152-9.

Anirban Basu

Education

  • PhD, Public Policy (Health Economics), University of Chicago, 2004
  • MS, Biostatistics, UNC-Chapel Hill, 1999
  • MS, Industrial Pharmacy, University of Toledo, 1997
  • BS, Pharmaceutical Technology, Jadavpur University India

Courses Taught

  • Welfare Economics foundations for cost-effectiveness analysis (HSERV 583, ’11 & ‘12) – 1.5 hour sessions
  • Understanding the role of uncertainty in decision models (HSERV 583, ’13 & ‘14) – 1.5 hour sessions
  • Quantitative methods for valuing information in health care (HSERV 584, ‘11) – 1.5 hour sessions
  • Introduction to comparative effectiveness methods (HSERV 523, ’11; HSERV 513 & HSERV 592, ’12) – 1.5 hour sessions
  • Instrumental variable methods (HSERV 523, ‘11) – 1.5 hour session
  • Financing healthcare (HuBio 555, ’13, ‘14) – 1.5 hour session to 250 2nd year medical students
  • Quantile regression methods (HSERV 525, ’11, HSERV 523, ‘12) – 1.5 hour sessions
  • Variations in healthcare spending: Observations & Implications (PHARM 568, ’14 -‘16) – 1.5 hour sessions
  • Causal inference in observational studies (HSERV 525), Spring 2013 -2019- Ten 3 hour sessions.

Research Interests

  • comparative and cost-effectiveness analyses
  • causal inference methods
  • program evaluation, and outcomes research

Biography

Anirban Basu, PhD, MS, is a health economist and a statistician who specializes in research on comparative and cost effectiveness analyses, causal inference methods, program evaluation, and outcomes research. He directs The Comparative Health Outcomes, Policy, and Economics (CHOICE) Institute at the University of Washington, Seattle, with appointments in the departments of Pharmacy, Health Services, and Economics at the university. He is a Faculty Research Fellow at the National Bureau of Economic Research, and a Fellow of the American Statistical Association. He was one of the panelists for the Second Panel on the Cost-Effectiveness Analysis in Health and Medicine. He studies heterogeneity in clinical and economic outcomes, micro behavior with respect to heterogeneous information, and the value of individualized care. He teaches topics in health economics, decision analysis, cost-effectiveness analysis, and health services research methods. He received his PhD in Public Policy (Health Economics Specialization) from The University of Chicago and an MS in Biostatistics from the University of North Carolina at Chapel Hill. http://faculty.washington.edu/basua/

Selected Publications

https://scholar.google.com/citations?user=AR72duAAAAAJ&hl=en